Nuveen
AUPH icon

Nuveen’s Aurinia Pharmaceuticals AUPH Stock Holding History

Nuveen’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.8M Buy
812,915
+159,491
+24% +$2.55M ﹤0.01% 1489
2026
Q1 		$9.68M Sell
653,424
-11,893
-2% -$174K ﹤0.01% 1574
2025
Q4 		$10.6M Buy
665,317
+360,084
+118% +$5.1M ﹤0.01% 1522
2025
Q3 		$3.37M Buy
305,233
+39,272
+15% +$429K ﹤0.01% 2096
2025
Q2 		$2.25M Sell
265,961
-979,588
-79% -$7.85M ﹤0.01% 2251
2025
Q1 		$10M Sell
1,245,549
-246,752
-17% -$2M ﹤0.01% 1554
2024
Q4 		$13.4M Buy
1,492,301
+138,054
+10% +$1.13M ﹤0.01% 1437
2024
Q3 		$9.93M Sell
1,354,247
-449,183
-25% -$2.79M ﹤0.01% 1614
2024
Q2 		$10.3M Sell
1,803,430
-255,677
-12% -$1.35M ﹤0.01% 1563
2024
Q1 		$10.3M Sell
2,059,107
-293,018
-12% -$1.99M ﹤0.01% 1566
2023
Q4 		$21.1M Sell
2,352,125
-338
-0% -$2.78K 0.01% 1123
2023
Q3 		$18.3M Buy
+2,352,463
New +$23M 0.01% 1094

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen's AUPH Position: Q2 2026 in Review

Nuveen increased its Aurinia Pharmaceuticals (AUPH) stake by 24% in Q2 2026, buying an estimated $2.55M and bringing the position to 812,915 shares worth $13.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1489.

Nuveen first reported a position in AUPH in Q3 2023 and has held it in 12 quarters since. The position peaked at $21.1M in Q4 2023. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Nuveen held 812,915 shares of Aurinia Pharmaceuticals worth $13.8M as of Q2 2026.
  • Nuveen bought 159,491 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $2.55M.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1489 holding.
  • Nuveen first reported a position in Aurinia Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • Nuveen's Aurinia Pharmaceuticals position peaked at $21.1M in Q4 2023.
  • 282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.